April 22, 2019
SanBio President Keita Mori (left) Tokyo-based biotech SanBio pledges to set up an in-house marketing system in Japan by 2020, when it plans to file its investigational stem cell therapy candidate SB623 for the treatment of traumatic brain injury for...read more